Irvine, California
Phase 3 cancer trials in Irvine, CA
48 Phase 3 cancer studies are recruiting participants at sites in Irvine as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Irvine at a glance
- 48 studies are recruiting at a site in Irvine.
- By phase: Phase 2/3 (6), Phase 3 (42).
- By sponsor: industry (23), university, hospital or other (18), government (7).
- By research area: Lung Cancer (14), Breast Cancer (13), Lymphoma (11), Prostate Cancer (6), Pancreatic Cancer (3), Melanoma (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Irvine
Basic details from each study's public record (the 30 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT07391774 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- City of Hope Lennar Foundation Cancer Center ( Site 0099)
- Registry record
- NCT06841354 · updated
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- City of Hope at Irvine Lennar
- Registry record
- NCT05894239 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- City of Hope at Irvine Lennar · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT06058377 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study site
- Kaiser Permanente-Irvine
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Kaiser Permanente-Irvine · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT06748222 · updated
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- City of Hope - Lennar Foundation Cancer Center
- Registry record
- NCT06790693 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- City of Hope Orange County Lennar Foundation Cancer Center
- Registry record
- NCT07174336 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Irvine, CA on ClinicalTrials.gov.
Lung cancer studies recruiting in Irvine
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-Irvine
- Registry record
- NCT07388524 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-Irvine
- Registry record
- NCT04267848 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building
- Registry record
- NCT07100080 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- UCI Health-CIACC
- Registry record
- NCT06793215 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- UCLA Hematology/Oncology - Irvine
- Registry record
- NCT07144280 · updated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Phase 3
- Ages 18 to 90
- All sexes
- Sponsor
- ImmunityBio, Inc.
- Study site
- City of Hope
- Registry record
- NCT06745908 · updated
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144
- Registry record
- NCT04928846 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Irvine, CA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Irvine
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- City of Hope at Irvine Lennar · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT07200830 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- City of Hope Lennar Foundation Cancer Center ( Site 0059)
- Registry record
- NCT06925737 · updated
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT05946213 · updated
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120)
- Registry record
- NCT06136650 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Irvine, CA on ClinicalTrials.gov.
Melanoma studies recruiting in Irvine
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Irvine, CA on ClinicalTrials.gov.
Lymphoma studies recruiting in Irvine
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- City of Hope at Irvine Lennar · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT06337318 · updated
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT06724237 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- City of Hope at Irvine Lennar · Kaiser Permanente-Irvine · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- City of Hope at Irvine Lennar · UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT05675410 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT03150693 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
- Registry record
- NCT07215910 · updated
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Phase 3
- Ages 65 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Kaiser Permanente-Irvine
- Registry record
- NCT07321652 · updated
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Kaiser Permanente Southern California
- Registry record
- NCT06742996 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Irvine, CA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Irvine
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- UCI Health - Irvine
- Registry record
- NCT07409272 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Irvine, CA on ClinicalTrials.gov.
Ask about studies near Irvine
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in California
All California locations
186 studies recruiting across 133 cities.
Los Angeles
95 studies recruiting.
San Francisco
63 studies recruiting.
Orange
46 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections